Allergy, Asthma & Respiratory Disease pissn eissn 투고규정 I. 출판원칙 알레르기천식호흡기질환 (Allergy, Asthma & Respiratory Disease [Allergy Asthma

Transcription

1 Allergy, Asthma & Respiratory Disease pissn eissn 투고규정 I. 출판원칙 알레르기천식호흡기질환 (Allergy, Asthma & Respiratory Disease [Allergy Asthma Respir Dis]) 의투고규정은 Good Publication Practice Guidelines for Medical Journals ( html, Korean Association of Medical Journal Editors), Guidelines on Good Publication ( Committee on publication ethics), Committee on Publication Ethics, and Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication ( icmje.org, International Committee of Medical Journal Editors [ICMJE]) 에서규정한요건을따른다. 각저자는원고를게재할때아래의모든규정을준수해야한다. 1. 저자자격 Allergy Asthma Respir Dis 는저자를연구에참여하였고원고의모든내용에공적으로책임을질수있는사람으로정의한다. 모든저자는다음의과정에충분히기여해야만한다. 1) 연구의구상과디자인, 데이터수집, 분석, 해석 2) 초안작성, 연구내용의중요한부분에대한수정 3) 접수한원고의최종승인저자가그룹일때모든저자는위의조건을만족해야하고연구의질, 정확도, 윤리에책임을가져야한다. 모든저자는저자순서를정할때참여해야한다. 2. 윤리연구윤리 Allergy Asthma Respir Dis 에원고를게재하기위해서는인간을대상으로한연구는헬싱키선언 ( 10policies/b3/index.html) 의원칙과권고사항을따라야한다. 이요건을만족하기위해서저자는연구대상에게적절한고지에입각한동의서를받아야만한다. 연구프로토콜은인간연구에대한공식 IRB (Institutional Review Board) 에의해검토되고승인되어야한다. 저자는원고의방법에서 IRB 승인을받았다는기술을하여야하며, IRB 승인이불필요한경우에는 IRB 로부터 IRB 승인이불필요하다는공식적허락을받아야한다. 증례같이방법이없는경우에는표지에 IRB 승인을표시해야한다. 실험동물을사용한경우실험동물의사용과관리에대한연구소와국가가이드라인 (Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 을따르는지를기술해야한다. 이해관계이해관계란저자, 저자소속기관, 심사위원, 편집위원사이에각자의행위에부적절한영향을미칠수있는재정적또는개인적관계를의미한다. 모든저자는예를들면다음과같은이해관계를밝혀야한다. 1) 재정적관계 ( 고용, 자문, 주식소유권, 사례금, 전문감정사례비 ), 2) 개인적관계, 3) 학문적경쟁관계, 4) 지적욕구. 이러한이해관계는표지에각주로또는감사의글부분에기술되어야한다. 개인정보보호와동의서저자는원고에서환자와연구대상을식별할수있는문구 ( 환자의성명, initials, 주민등록번호, 병록번호 ) 를삭제해야한다. 이러한문구는과학적목적이라면포함될수도있으며저자는환자또는보호자에게문서로동의서를받아야한다. 출판윤리원고는 Allergy Asthma Respir Dis 에만투고되고기존에출판된논문과중복되지않는경우에만출판이고려될것이다. 가설, 연구대상의특징, 방법, 결과, 결론이기존출판된논문과유사한경우에는중복게재로간주된다. Allergy Asthma Respir Dis 는또한 salami 출판을금지한다. Salami 출판이란단일한연구과정또는단일한연구기간에얻은자료를부분으로잘라서동일한또는다른잡지에여러편의원고를게재하는것을포함한다. 3. 저작권투고된원고가게재허가가되면저자들은저작권에관한동의서를서명한후팩스로보내거나온라인으로접수한다 (FAX: , aard@aard.or.kr). 모든출판논문은영구적으로대한소아알레르기호흡기학회와대한천식알레르기학회의소유이며출판물의저작권에관한모든권한도대한소아알레르기호흡기학회와대한천식알레르기학회에있다. 저작권은 Creative Commons Attribution Non-Commercial License 를따른다 ( 출판물의상업적사용에대해서는대한소아알레르기호흡기학회와대한천식알레르기학회의허가가필수적이다. II. 원고의심의 원고를투고한다는것은모든저자가 Allergy Asthma Respir Dis 의출판원칙을준수한다는것을의미한다. 투고된원고는과거에출판된적이없으며, 다른학술지에출판을고려하고있지않아야한다. 3 인의해당분야전문가에게심의를요청하고그결과를고지하게된다 : 1 통과, 2 수정후게재, 3 수정후재심사, 4 게재불가, 5 자문심사. 어떠한상황에서도심사자의신원은비밀로유지된다. 새로운저자를추가해야하거나기존저자를삭제하려면책임저자는모든저자들이저자의변화를알게해야하고동의하는지를확인해야만한다. Allergy Asthma Respir Dis 는그러한변화에대한책임을지지는않는다. 모든출판된원고의저작권에관한모든권한을대한천식알레르기학회와대한소아알레르기호흡기학회가가지며, 문서로작성된허가없이다른잡지에출판되지않을것이다. 본학회지의성격에맞지않는주제이거나, 논문투고형식점검표를정확히이행하지못한경우는심사하지않고저자에게돌려보내지며, 저자가투고규정에따라논문을재작성하면다시접수할수있다.

2 III. 원고제출 원고제출시 Allergy Asthma Respir Dis 홈페이지 ( 에접속하여 논문접수및심사 란을클릭하여로그인한후접수자란에들어가서저자명과소속등을기재한후논문을첨부하거나기재하여투고한다. 제출시책임저자의주소, 전화번호, 팩스번호, 이메일주소를명시해야한다. 원고는한글원고를원칙으로하며초록은영문으로작성한다. 한글원고에서학술용어는원칙적으로의학용어집제 5 판 ( 대한의사협회발행 2009) 을참고하여한글로작성한다. 적절한번역어가없는의학용어, 고유명사, 약품명, 단위등은원어를그대로사용한다. 번역어가있으나의미전달이명확하지않은경우에는그용어의최초번역어다음소괄호속에원어를표기하고그이후로는번역어만사용한다. 인명, 지명등의고유명사는원어로표기한다. 원고는 Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication ( updated March 2009 를따라서제출되어야한다. 원고는 Microsoft 2000 이상의워드프로그램을사용하는것을원칙으로하며한글 97 이상도사용가능하다. 원고는맞춤법과띄어쓰기를정확히하여작성하며글씨크기는 12 point, 줄간격은두줄간격으로좌우 2 cm 및상하 3 cm 의여백을둔다. 괄호 ( ) 를사용할때의띄어쓰기는괄호앞에영문이나숫자가올때는띄어쓰기를하고국문이올때는띄어쓰기를하지않고붙여서쓴다. 페이지번호는제출원고의표지를 1 로하여각페이지하단중앙에순차적으로표시한다. 행번호는원고의좌측에표시해야만하며각페이지에서새롭게시작하지않고이어서매겨야한다. 1. 원저원고의총길이는초록, 참고문헌, 표, 그림설명을제외하고 3,000 단어이내로한다. 표와그림의총수는 10 개미만이어야한다. 원저의구성은 1 표지 (title page), 2 영문초록 (abstract) 및색인 (keywords), 3 서론 (introduction), 4 대상및방법 (materials and methods), 5 결과 (results), 6 고찰 (discussion), 7 감사의글 (acknowledgement), 8 참고문헌 (references), 9 표 (table), 10 그림설명 (legend), 그림 (figure) 의순서로한다. 표지표지에는논문제목, 저자명, 저자의소속기관을기재한다. 제목은논문의목적을간결하게표현해야되며, 연구방법이중요한경우부제목으로설정할수있다. 한글제목은 30 자, 영문제목은 15 단어를넘지않도록하고, 각면의머리글로표기할수있도록축약된제목 (running title) 을첨부해야한다. 소속기관이다른경우해당저자의성명끝에아라비아숫자를위첨자로표시하고소속기관을순서대로표기한다. 표지하단에책임저자의성명, 우편번호, 주소, 전화및팩스번호, 주소를표기한다. 또한연구비지원수혜등을표지에기재한다. 초록초록은영문으로작성하며, 저자, 소속, 색인용어를제외하고 250 단어이내로하고구조화된형식으로작성한다 : purpose, methods, results, conclusion 으로나누어작성한다. 약어의사용은최소화한다. 영문이름은 full name 을기재하며학위 (MD, PhD) 는사용하지않는다. 키워드초록하단에 keywords 는 5 단어이내로기재하며 Index Medicus 의 Medical Subject Headings (MeSH) 에등재된단어를선택한다 ( ncbi.nlm.nih.gov/mesh). 서론서론은논문의목적과가설을기술하며, 연구또는관찰의이론적근거를간결하고명료하게제시한다. 배경에관한기술은목적과연관이있는내용만포함하며본논문에서보고하는연구결과나결론은넣지않는다. 대상및방법연구의계획, 대상선택및방법의순서로간결하면서충분히기술한다. 연구대상이환자인경우에는나이, 성별, 다른특징, 질병의진단방법등을기술한다. 연구방법은구체적이고자세히기술하여재현이가능하도록한다. 잘확립된실험방법에대해서는참고문헌을써주고잘알려져있지않은방법은참고문헌과함께방법을간단히기술한다. 새로운방법과변형된방법을사용할때에는그방법을사용한이유와그방법의한계점에대해기술한다. 약품과화학제품은속명 (generic name), 용량, 투여방법에대해정확히기술한다. 연구에사용한기계및시약의출처를제조회사, 도시, ( 주 ), 국가의순으로표시해야한다. 통계는자료를가지고결과를증명할수있도록충분히상세한방법을기술하여야하며, 통계적유의수준을명시해야한다. 결과연구결과를명료하게나열하고, 같은내용에관한표 (Table) 와그림 (Figure) 은꼭필요한경우에만사용하여두개를함께중복설명하지않아야한다. 본문에서는표와그림의모든내용을중복기술하지말고중요한요점만강조한다. 고찰연구결과에대한고찰이나이에관련된다른자료와의연관성을기술한다. 연구의새롭고중요한관찰의의미및제한점을기술하되서론이나결과에기술된것들을중복기술하지않는다. 결과를토대로결론에이르는과정을논리적으로기술한다. 고찰의끝부분에결론을기술한다. 감사의글필요한경우, 이연구에기여를한사람으로저자에포함되기에는부족한사람에대한감사의글을넣을수있다. 여기에는어느역할에대해감사하는지명백하게표현하여야하며 ( 예를들어자료수집, 재정적보조, 통계처리, 실험분석등 ), 저자는그사람에게감사의글에이름이나온다는사실을통보하고사전에동의를받아야한다. 참고문헌참고문헌의숫자는원저는 40 개이하로한다. 모든참고문헌은국내외논문에관계없이영문으로기재하며, 인용순서대로아라비아숫자번호로기재하고, 본문에 어깨번호 를표시한다. 기록된참고문헌은반드시본문에서인용되어야한다. 출판되지않은자료는참고문헌에기술될수없다. 저자명은영문으로성뒤에생략부호없이이름의약자만표기하고 6 명의공동저자까지기입하며, 7 명이상인경우에는 6 번째저자명뒤에 et al. 을붙인다. 학술지명은 Index Medicus 의공인약어를사용한다. 참고문헌표기양식의예는다음과같으며, Allergy Asthma Respir Dis 투고웹사이트에서 Allergy Asthma Respir Dis EndNote style 을사용할것을권장한다. 밑의예에언급되지않은참고문헌표기는 NLM guide for authors, editors, and publishers (2007). 2nd ed. National Library of Medicine, Bethesda (MD), USA ( 를따른다. 학술지정기학술지 Forno E, Lasky-Su J, Himes B, Howrylak J, Ramsey C, Brehm J, et al. Genome-wide association study of the age of onset of childhood

3 asthma. J Allergy Clin Immunol 2012;130: 저자가그룹일경우 Early Treatment of the Atopic Child. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998;9: 권의부록 de Groat WC, Kawatani M, Hisamitsu T, Cheng CL, Ma CP, Thor K, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990;30 Suppl: S71-7. 호의부록 Pedersen S, O Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52(39 Suppl):1-34. 권이없는호 Bameister AA. Origins and control of stereotyped movements. Monogr Am Assoc Ment Defic 1978;(3): 단행본저자가 2 명이하 Roitt IM. Essential immunology. 8th ed. Oxford: Blackwell Scientific Publications, 단행본의장 Ellis EF. Asthma in infancy and childhood. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 4th ed. St. Louis: Mosby, 1993: 학술대회초록 Vivian VL, editor. Child abuse and neglect: a medical community response [abstract]. In: Proceedings of the First AMA National Conference on Child Abuse and Neglect; 1984 Mar (meeting date); Chicago (meeting place), USA (meeting country). Chicago (academy location): American Medical Association (academy name), 1985 (publication year). Bae YM, Kil CH. Choi YM, Bae CW. The changes in the mortality rates of low birth weight infant and very low birth weight infant in Korea over the past 40 years [abstract]. In: Program and Abstract, the 53rd Annual Fall Meeting of the Korean Pediatric Society; 2003 Oct 24-25; Seoul, Korea. Seoul: The Korean Pediatric Society, 2003; 33. 학위논문 Youssef NM. School adjustment of children with congenital heart disease [dissertation]. Pittsburgh (PA): Univ. of Pittsburgh, 웹사이트 International Committee of Medical Journal Editor. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication [Internet]. Philadelphia: International Committee of Medical Journal Editor, c2009 [cited 2013 Jam 1]. Available from: 2. 종설종설은특정제목에초점을맞춘고찰로서편집위원회에서위촉하여게재한다. 투고규정은원저에준하나 1) 제목 ( 요약제목포함 ), 저자 ( 소속, 성명 ), 2) 초록 (unstructured, 250 자이내 ) 및키워드 3) 서론, 4) 본론, 5) 결론, 6) 감사의글, 7) 참고문헌의순서로기술하며그길이는한글 5,000 단어로제한하며, 참고문헌의제한은없다. 3. 증례투고규정은원저에준하나 1) 제목 ( 요약제목포함 ), 저자 ( 소속, 성명 ), 2) 초록 (unstructured, 250 단어이내 ) 및키워드, 3) 서론, 4) 증례, 5) 고찰, 6) 참고문헌의순서로기술하며, 전체길이는한글 1,500 단어로제한하며, 참고문헌은 20 개이내로제한한다. 4. 논평학회지에출판된특정논문에대한논평과그분야의최신지견을편집위원회에서의뢰하여집필되는것으로학회의의견을반영하는것은아니다. 원고의길이는한글 1,000 단어이내이고, 참고문헌은 10 개이내로제한한다. 5. Letter to the Editor Letter to the Editor 는 Allergy Asthma Respir Dis 에최간출판된논문과관련된것으로원고의수준과잡지의지면을고려하여편집자가심사하고승인한다. 원고의길이는한글 500 단어이내이고참고문헌은 7 개이내로제한다. 제목, unstructured 본문과참고문헌으로구성된다. 한개의표또는그림을허용한다. 6. 표, 그림영문과아라비아숫자로간결하게작성한다표의제목은표의상단에명료하게절과구의형태로기술하며, 첫자만대문자로한다. 표내에는약어를사용할수있는데이때표하단에각주로표시한다. 표내에는수직선이나횡선을사용하지않고표를작성한다. 표의내용은이해하기쉬워야하며, 독자적기능을할수있어야한다. 표의분량은 4 줄이상의자료를포함하여 1 쪽을넘지않아야한다. 이미출간된논문의표와동일한것은사용할수없다. 각주의표시는위첨자표기로하며 *,,,,,, ** 순으로한다. 그림의제목과설명은별지에영문으로구나절이아닌문장형태로기술한다. 그림 (line drawing) 의경우흰바탕에검은선을사용하며선명하고전문적이어야한다. 동일번호에는 2 개이상의그림인경우에는 Fig. 1A, Fig. 1B 순으로표시하며, 그림의상하좌우가바뀌지않게하며 Tiff, EPS 혹은고해상도 JPG 파일로제출한다. 그림의너비는 4 inches 로하고, 디지털해상도는흑백그림의경우최소한 900 DPI/PPI 이상, 사진의경우 300 DPI/PPI 이상, 화살표및선이들어가는사진의경우 600 DPI/PPI 이상되어야한다. 그림과표는동일한글자체로통일하는것을원칙으로한다. 본문중에표와그림을인용할때는 Table 과 Fig. 로표기한다. 7. 단위및약어단위는원칙적으로 SI 단위 (International System of Units) 를사용한다. 단위는 %, C 를제외하고는한칸씩띄운다. 영문약어는최소화하고, 본문에일정용어가반복되어부득이약자를사용하여야하는경우에는그용어가처음나올때괄호안에약어를함께표기하고다음부터약어를사용할수있다. 단논문제목에서는약어를사용하지않는다. 8. 기타규정본문중에인용하는저자는성만을기재하며, 저자가 1 인경우에는 Smith 1) 는, 2 인인경우 Lee 와 Park 2) 은, 3 인이상인경우 Edward 등 3) 으로표기한다. 미생물의학명은이탤릭체로표기하며, 처음표기시에는전체이름을표기 ( 예 : Echerichia coli) 하고이후에는종명 (genus) 은생략한다 (E. coli). 통계처리법에관한설명시, 사용된통계방법에대한정확한기재와논문에서사용된의미있는 P 값을구간을설명한다 (P<0.05). 그러나최근 P 값에관해계산된 P 값을직접표시하는경향이있어이를사용해도무방하다 ( 예 : P=0.0004). P 자는대문자이탤릭체로표기한다.

4 9. 교정지원고의게재가확정되면최종교정을위하여책임저자에게인쇄교정지가 PDF 파일로발송된다. 수정은최소화하기를권유하며, 발송된지 48 시간안에 또는 Fax 로 Allergy Asthma Respir Dis 편집위원회에회신하여야한다. 10. 게재료및인쇄료원저또는증례보고에있어서소정의게재료를받는다. 도안료와그밖의특수인쇄를필요로할경우에는그비용을저자가부담한다. 필요한별책의부수는최종인쇄교정지의해당란에표시한다. 투고규정과관련된상세한사항이필요한경우에는 Allergy Asthma Respir Dis 편집위원회에연락할수있으며 를방문하여정보를얻을수있다.

5 Allergy, Asthma & Respiratory Disease pissn eissn Instructions to Authors I. Journal Publication Policies and Ethics Allergy Asthma Respir Dis has agreed to follow the Good Publication Practice Guidelines for Medical Journals ( Korean Association of Medical Journal Editors), Guidelines on Good Publication ( guide lines, Committee on publication ethics), Committee on Publication Ethics, and Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication ( International Committee of Medical Journal Editors [ICMJE]). The manuscript submission instructions are consistent with the March 2009 version of the Uniform Requirements. Each author is responsible for fully understanding all requirements listed below. Authors must submit all manuscripts. To submit a manuscript, please prepare it according to Guidelines for Manuscript Preparation. A. Authorship and Contribution Allergy Asthma Respir Dis defines author as a person whose participation in the work is sufficient for taking public responsibility for all portions of the content. Specifically, all authors should have made substantial contributions to all of the following: 1) conception and design of the study, or acquisition of the data, or analysis and interpretation of data; 2) drafting of the article or critical revision of the article for important intellectual content; and 3) final approval of the version to be submitted. When authorship is attributed to a group, all authors must meet the listed criteria and must be responsible for the quality, accuracy, and ethics of the work. All authors must participate in determining the order of authorship. B. Ethics Research Ethics For submission to Allergy Asthma Respir Dis, studies on human being must comply with the principles of the Declaration of Helsinki ( and its recommendations guiding physicians in biomedical research involving human subjects. To satisfy this requirement, authors must obtain appropriate informed consent from study subjects. Investigational protocols must have been reviewed and approved by a formally constituted the Institutional Review Board (IRB) for human studies. Authors must state in their Methods section that they have received IRB approval for their study or have received a statement from the IRB that IRB approval was unnecessary. In the submission of selected series such as case reports that have no Methods sections, authors must address IRB approval in the cover letter to Allergy Asthma Respir Dis. When reporting experiments in animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed. Conflict of interest Conflict of interest exists when an author (or the author s institution), reviewer, or editor has financial or personal relationships that inappropriately influence his/her actions (such relationships are also known as dual commitments, competing interests, or competing loyalties). All authors should disclose their conflicts of interest, i.e., 1) financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony), 2) personal relationship, 3) academic competition, and 4) intellectual passion. These conflicts of interest must be included as a footnote on the title page or in the acknowledgement section. Each author should certify the disclosure of any conflict of interest with his/her signature. Privacy and Informed Consent Authors must omit from their manuscripts any identifying details regarding patients and study participants, including patients names, initials, identification card numbers, and hospital numbers. Patient details may be included only if they are essential for scientific purposes and the authors obtain written informed consent for publication from the patient, parent, or guardian. Publication Ethics Submissions will be considered for publication in Allergy Asthma Respir Dis only if they are submitted solely to Allergy Asthma Respir Dis and do not overlap substantially with a previously published article. Any manuscript with a hypothesis, sample characteristics, methodology, results, and conclusions that are similar or nearly similar to those of a published article is considered a duplicate article and is prohibited. Allergy Asthma Respir Dis also prohibits so-called salami publishing which involves the slicing of data collected from a single research process or single study period into different pieces to form the basis of multiple manuscripts published in different journals or the same journal. C. Copyrights and Creative Commons Attribution License Upon acceptance of their article, the authors will be asked to sign a Journal Publishing Agreement (for more information on publishing and copyright, see the Transfer of Copyright form), and should send the transfer copyright to publication committee of Allergy Asthma Respir Dis by fax ( ) or (aard@aard.or.kr). All published papers become the permanent property of Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) and the Korean Academy of Asthma, Allergy, and Clinical Immunology (KAAACI). Copyrights of all published materials are owned by the KAPARD and the KAAACI. They also follow the Creative Commons Attribution Non-Commercial License available from: For any commercial use of material

6 from the open access version of the journal, permission must be obtained from the KAPARD and the KAAACI. Every author should sign the authorship responsibility and copyright transfer agreement form, attesting that he/she fulfills the authorship criteria. Authors are required to identify their contributions to the work described in the manuscript. The manuscript, when published, will become the property of the journal. II. Editorial Policy The Editor assumes that on submission of a manuscript, all listed authors have agreed with the following Allergy Asthma Respir Dis policies. A manuscript submitted to Allergy Asthma Respir Dis must not have been previously published and must not be under consideration for publication elsewhere. Three reviewers will examine a manuscript, and the publication committee will notify the results: 1 accept, 2 accept with minor revision, 3 major revision recommended, 4 reject, 5 consultation review. Under no circumstance will the identities of referees be revealed. If a new author should be added or an author should be deleted after the submission, it is the responsibility of the corresponding author to ensure that all concerned authors are aware of and agree with the change in authorship. Allergy Asthma Respir Dis has no responsibility for such changes. All published manuscripts become the permanent property of the Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) and Korean Academy of Asthma, Allergy, and Clinical Immunology (KAAACI) and may not be published elsewhere without written permission. Submitted manuscript will be sent back to the author unless its topics fit Allergy Asthma Respir Dis scope or it fulfill author s check list. III. Manuscript Submission All manuscripts must be submitted to online through the Allergy Asthma Respir Dis e-submission system at All materials must be written in proper and clear Korean. At the time of submission, complete contact information (mailing address, telephone number, fax number and address) for the corresponding author is required. First and last names, abbreviated-highest academic degrees, addresses, and institutional affiliations of all co-authors are also required. The following items are required at the time of submission: title page, main text, image file. Manuscripts should be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication ( updated October Microsoft Word (doc, docx) or Hangul Word Processor (hwp) is recommended for writing the manuscript. The entire manuscript should be in a standard font, size 12. Each manuscript component should be attached as a separate submission item, be double-spaced and have a 2 cm margin on left and right sides with a 3 cm margin on upper and lower sides. All pages should be numbered consecutively, starting with the title page as page. 1. Page numbering should begin with the manuscript file. The page number should appear in the lower center of each page. Line number (i.e., 1, 2, 3 etc.) should be displayed in the left-hand margin of the manuscript file. Line numbering can be added form the File/Page Setup menu of word processing programs and should be continuous throughout the manuscript file. Do not restart numbering from each page. For more information, please contact the journal editorial office directly: aard@aard.or.kr A. Original Article The total length should not exceed 3,000 Korean words (excluding the Abstract, Reference, and Tables/Figures Legends). The total number of tables and figures should be fewer than 10. Title page This should contain the Title of an article, full names and affiliations of all authors. The title should be concise and descriptive, should comprise fewer than 30 characters in Korean or 15 words in English. A running title should be included. For authors with different affiliations, place an Arabic number as a superscript after each author s last name and before the name of the corresponding affiliation. Provide corresponding author s name, address (institutional affiliation, city, state/province, zipcode, and country), telephone and fax numbers, and address at the bottom of the title page. Information concerning sources of financial support should be placed as a footnote. Abstract The abstract should be concise and be written in English, should contain fewer than 250 words, and should be organized in a structured format: Purpose, Methods, Results, and Conclusion. Abbreviations should be kept to an absolute minimum. Key words List five or less key words from the list provided Index Medicus or the Medical Subject Heading (MeSH) at Text The text must contain the following sections: 1) Introduction, 2) Materials and Methods, 3) Results, and 4) Discussion. Introduction This should states the specific purpose, research objective, or hypothesis of the study and should provide a context or background for the study. Papers most closely related to the issue under study may be mentioned. Materials and Methods The explanation of the experimental methods should be concise but sufficient to allow other workers to reproduce the results. This section provides technical information, apparatus details (manufacturer s name and brief address), and procedures. Provide references and brief descriptions for previously published methods. Describe statistical methods with sufficient detail to enable a reader with access to the original data to verify the reported results. Define statistical terms, abbreviations, and most symbols. Results The results should be presented logically, using text, tables, and illustra-

7 tions. Excessive repetition of table or figure contents should be avoided. Discussion The data should be interpreted concisely, without repeating data already presented in the results section. Speculation is permitted but must be supported by the presented data and be well founded. Conclusion should be described at the end of discussion section Acknowledgments All persons who have made a substantial contribution but are not eligible as authors are named in the acknowledgments section. Examples of those who may be acknowledged include person who provided purely technical help or writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance. References References should not exceed 40 for original article. All references must be identified in the text by superscript Arabic numerals and numbered in consecutive order, as they are cited in the text. The list of references, in numerical order, should be included at the end of the article. Authors are responsible for the accuracy and completeness of their references and the correct text citations. List all authors names when there are six or fewer; when there are seven or more, list the first six and add et al. Abbreviate journal names according to the examples used in Index Medicus and PubMed. References should follow the styles shown below, according to the sequence: authors, title of paper, journal name, year published, volume, inclusive page numbers. For citations from sources not listed below, refer to the NLM guide for authors, editors, and publishers (2007). 2nd ed. National Library of Medicine. Bethesda (MD), USA ( Papers in press may be listed among the references with the journal name and tentative year of publication. Unpublished data or personal communications can be listed only with the author s written permission. Examples of Reference Format: Journal Standard journal articles Forno E, Lasky-Su J, Himes B, Howrylak J, Ramsey C, Brehm J, et al. Genome-wide association study of the age of onset of childhood asthma. J Allergy Clin Immunol 2012;130: Journal article with organization as author Early Treatment of the Atopic Child. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998;9: Volume with Supplement de Groat WC, Kawatani M, Hisamitsu T, Cheng CL, Ma CP, Thor K, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990;30 Suppl:S71-7. Issue with supplement Pedersen S, O Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52(39 Suppl):1-34. Issue without volume Bameister AA. Origins and control of stereotyped movements. Monogr Am Assoc Ment Defic 1978;(3): Book Number of authors to 2 Roitt IM. Essential immunology. 8th ed. Oxford: Blackwell Scientific Publications, Chapter in a book Ellis EF. Asthma in infancy and childhood. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 4th ed. St. Louis: Mosby, 1993: Abstract, Conference proceeding Vivian VL, editor. Child abuse and neglect: a medical community response [abstract]. In: Proceedings of the First AMA National Conference on Child Abuse and Neglect; 1984 Mar (meeting date); Chicago (meeting place), USA (meeting country). Chicago (academy location): American Medical Association (academy name), 1985 (publication year). Bae YM, Kil CH. Choi YM, Bae CW. The changes in the mortality rates of low birth weight infant and very low birth weight infant in Korea over the past 40 years [abstract]. In: Program and Abstract, the 53rd Annual Fall Meeting of the Korean Pediatric Society; 2003 Oct 24-25; Seoul, Korea. Seoul: The Korean Pediatric Society, 2003;33. Dissertation Youssef NM. School adjustment of children with congenital heart disease [dissertation]. Pittsburgh (PA): Univ. of Pittsburgh,1988. Website International Committee of Medical Journal Editor. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication [Internet]. Philadelphia: International Committee of Medical Journal Editor, c2009 [cited 2013 Jan 1]. Available from: main.html. B. Review Article Review articles are usually solicited by the Editor-in-Chief. Authors should contact the Editor-in-Chief in advance to determine the appropriateness of any proposed review. A review article should include a Title page (with a running head), an Abstract (unstructured, fewer than 250 words), Key Words, Text including conclusion, References, Table, and Figures. The total length is recommended to be within 5,000 Korean words, and references are unlimited. C. Case Report A Case Report should comprise an Abstract (unstructured, fewer than 250 words), Key Words, Introduction, Case Report, Discussion, and References. The total length is within 1,500 Korean words. References should not exceed 20. D. Editorial Editorials are commissioned to relate to papers appearing in the journal. The total length should not exceed 1,000 Korean words, and references should not exceed 10. No abstract is required for editorials. E. Letter to the Editor Letter to the Editor concerning recent publications in the AARD will be

8 published through review and approval by the editors when its scientific quality is acceptable and space in the AAIR is available. A Letter to the Editor should be concise and no longer than 500 words. It should have a title, distinct from the title of the referenced article, an unstructured main content, and a list of references which should be no more than seven. Only one graphic presentation would be accepted. F. Tables and Figures Each table should fit within a single page. The table legend may include any pertinent notes and must include definitions of all abbreviations and acronyms used in the Table. For footnotes, the following superscript symbols should be used in this order *,,,,,, **. The significance of observations must be indicated by appropriate statistical analysis. If you include a table or figure in a manuscript, it should be referred to in the text as Table and Fig,, respectively. Figures are to be cited consecutively, using Arabic numerals. Figures that are drawn or photographed professionally should be sent as Tiff, EPS, or high resolution JPEG files. Authors should review the images of the files on a computer screen to ensure that meet their own quality standards. It is recommended to size original figure widths to 4 inches wide. The minimum requirements for digital resolution are: DPI/PPI for black and white images, such as line drawings or graphs DPI/PPI for picture-only photographs DPI/PPI for photographs containing pictures and line elements, i.e., text labels, thin lines, arrows. G. Abbreviations and Unit of Measurements Authors should limit the use of abbreviations to an absolute minimum. Abbreviations are not to be used in titles. Abstracts may contain abbreviations for terms mentioned many times in the Abstract, but each term must be defined at the first time it is mentioned. Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter, or their decimal multiples). Temperature should be in degrees Celsius. H. Other Instructions Authors cited in the text are expressed as a Smith 1) for one author, Lee and Park 2) for two authors, and Kim, et al. 3) for 3 authors or more. Name of microorganism should be expressed as an italic, be described in full name (Echerichia coli) at the first time, and then in abbreviation (E. coli). Every P value can be reported as a P<0.05, and also as an actual value (P=0.0004). P should be written as an italic capitalized letter. I. Page Proofs Allergy Asthma Respir Dis will provide the corresponding or first author with galley proofs for review/correction. Corresponding authors will receive a PDF file of the typeset pages to check the copyediting before publication. Corrections should be kept to a minimum. Within 48 hours, changes to page proofs should be sent by or Fax to the Allergy Asthma Respir Dis Editorial Office. The corresponding author may be contacted by the Editorial Office, depending on the nature of the correction in the proof. Failure to return the proof to the Editorial Office within 48 hours may necessitate rescheduling publication for a subsequent issue. J. Fee for Publication Processing and Reprints Nominal fee is charged for publication processing. The reprint order form must be returned along with the corrected galley proofs. Purchased reprints are normally shipped 3 weeks after publication of the journal. Minimum publication charges and additional fee for reprints will due on every manuscript. Color illustrations are charged to the authors. For more information, please contact: Allergy Asthma Respir Dis Editorial Office

9 Allergy, Asthma & Respiratory Disease pissn eissn 저자점검표 점검사항 1. A4 용지에줄간격은두줄간격으로하며, 글씨크기는 12 point, 워드파일 (doc, docx 또는 hwp 파일 ) 로작성하였다. 2. 원고는표지, 영문초록및색인, 서론, 본문 ( 종설 : 본론, 결론, 원저 : 대상및방법, 결과, 고찰, 증례 : 증례, 고찰 ), 감사의글, 참고문헌, 표 / 그림설명 / 그림의순서이며, 표지를첫페이지로하여페이지번호를매겼다. 3. 표지는제목 ( 한글 30 자, 영문 15 단어이내 ), 저자이름, 소속, 책임저자정보 ( 주소, 전화번호, 팩스번호, 이메일주소 ), 요약제목을기재하였다. 4. 초록은 250 자이내로작성하였으며투고규정에제시한형식을따랐다. 초록의색인은 MeSH 권장단어를사용하여 5 단어이내로작성하였다. 5. 원고 ( 초록, 참고문헌, 그림설명, 표제외 ) 의분량은원저의경우 3,000 단어, 종설은 5,000 단어, 증례는 1,500 단어, 논평은 1,000 단어를초과하지않았다. 6. 사용된모든표와그림은본문중에표시하였다. 7. 참고문헌은투고규정에서정한형식에따라작성하였고, 모든참고문헌은본문중에표시하였으며, 인용된자료는모두참고문헌으로표시하였다. 8. 제출한원고의내용은다른학회지에게재되었거나게재될예정이없으며, 내용과관련된모든저자들의이해관계및재정지원을표지에명시하였다. 모든저자들을대표하여, 년월일 책임저자 ( 서명 )

10 Allergy, Asthma & Respiratory Disease pissn eissn Checklist for Authors Requirements 1. Typed double-spaced in 12-point font on A4 or letter-size paper and prepared as an electronic file using Microsoft Word (doc or docx) or Hangul Word Processor (hwp). 2. Sequence: title page, abstract and keywords, introduction, body (review: main body and conclusion, original article: materials and methods, results, and discussion, case report: case and discussion), acknowledgment, references, tables, figure legends, and figures. All pages should be numbered consecutively, starting from the title page. 3. Title page with article title (fewer than 30 characters in Korean or 15 words in English), authors full name(s) and affiliation(s), corresponding author (include phone and fax numbers and address), running title, and footnotes, if any. 4. Abstract within 250 words and five or less keywords from MeSH. 5. Total text does not exceed 3,000 words (excluding abstract, references, and figure/table legends) for original article, 5,000 words for review article, 1,500 words for case report, and 1,000 words for editorial. 6. All table and figure numbers appear in the text. 7. References are listed in proper format. All listed references are cited in the text, and vice versa. 8. A cover letter stating that the material has not been published previously and will not be submitted for publication elsewhere and reporting all conflicts of interest for all listed authors. The corresponding author name on behalf of all coauthors Your Signature Date Signed

11 Allergy, Asthma & Respiratory Disease pissn eissn 저작권이양동의서 국문제목 : 영문제목 : 저자 ( 들 ) 은본논문이 Allergy Asthma Respir Dis 에게재되길희망하며, 다음사항들에대하여확인및동의합니 다. 모든저자들을대표하여책임저자가다음사항에대하여대표로서명할수있습니다. 1. 본논문은과거에출판된적이없으며, 현재다른학술지에게재를목적으로제출되었거나제출할계획이없 습니다. 2. 본논문은위조, 변조, 표절이없는독창적인연구임을확인합니다. 3. 모든저자들은본논문에실제적인공헌을하였으며, 본논문의내용을최종확인하였습니다. 또한본논문의 내용에연구윤리를위반하는부정이있을경우함께책임을질것에동의합니다. 4. 본논문이다른논문이나연구자의저작권을침해하지않았음을확인합니다. 5. 본논문이 Allergy Asthma Respir Dis 에게재될경우, 저작권에관한모든권한을대한천식알레르기학회 와대한소아알레르기호흡기학회에이양하기로동의합니다. 모든저자들을대표하여, 년월일 책임저자 ( 서명 )

12 Allergy, Asthma & Respiratory Disease pissn eissn Copyright Transfer Agreement Manuscript Title : Author(s) must read and sign the statements below about authorship responsibility and copyright transfer. In the case of an article having more than one author, the signature of one of the authors is sufficient, provided that the signing author understands that he or she is signing on behalf of all of the authors and that all the other authors understand that the signing author is acting as their proxy in signing the manuscript submission form. 1. The manuscript has not been previously published and is not currently under consideration for publication elsewhere, nor will the research reported be submitted for publication elsewhere until a final decision has been made as to its acceptability by Allergy Asthma Respir Dis. 2. The manuscript represents truthful and original work without fabrication, fraud, or plagiarism. 3. All authors have made an important scientific contribution to the study and are thoroughly familiar with the primary data. All authors have read the complete manuscript, take responsibility for the content and completeness of the manuscript, and understand that they share responsibility if the paper, or part of the paper, were found to be faulty or fraudulent. 4. This manuscript contains no violation of any existing copyright or other third-party right, and to the best of the authors knowledge, this work does not infringe the rights of others. 5. In case of the acceptance of the above work for publication, the author(s) assign(s) and transfer(s) to the Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD) / Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI) all rights, title, and interest in and to the copyright in the above-titled work. The corresponding author name on behalf of all coauthors Your Signature Date Signed